- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02613559
Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration
February 27, 2018 updated by: Jiangsu T-Mab Biopharma Co.,Ltd
A Single-center, Open-label, Single Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Tolerability of Intravitreal TK001(Recombinant Humanized Anti-VEGF Monoclonal Antibody) in Subjects With Neovascular Age-Related Macular Degeneration
The purpose of this first-in-human study is to evaluate the safety, pharmacokinetics and tolerability of single ascending doses of TK001(Recombinant humanized anti-VEGF monoclonal antibody) to determine the maximum tolerated dose (MTD) in neovascular wet age-related macular degeneration (wAMD) subjects.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, non-comparative, non-randomized, single-center phase 1 study evaluating pharmacokinetics, safety and tolerability of single intravitreal injections of TK001 in the patients with AMD.TK001 is a full-length recombinant humanized anti-VEGF monoclonal antibody.
Compared with Avastin(a similar marketed product), the findings of preclinical studies suggested that TK001 might be more effective in inhibiting pathological angiogenesis, or to achieve equivalent effect with less dosage and better safety.
In this study, participants will be administrated a single dose of TK001.Every subject will only accept one dose.
In addition to safety and preliminary efficacy, pharmacokinetics and immunogenicity of TK001will be evaluated as well.
Study Type
Interventional
Enrollment (Anticipated)
27
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Guangfu Li
- Email: guangfuli@t-mab.com
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610000
- Recruiting
- West China Hospital, Sichuan University
-
Contact:
- Ming Zhang
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients or their legal representative signed informed consent
- Aged 45 years to 80 years, male or female
- Inpatient/Outpatient with confirmed neovascular AMD
- Best corrected VA for the studied eye≤20/100
- With primary or recurrent subfoveal choroidal neovascular (CNV) lesions secondary to neovascular AMD
- Blood pressure is stable with SBP<140 mmHg and DBP<90 mmHg with or without treatment
Exclusion Criteria:
Limitation of eye diseases
- The studied eye suffered intravitreal blood within two months prior to screening
- The studied eye suffered structural damage of retinal which involved macular center(such as epiretinal membrane, scars, laser burns, foveal atrophy, dense pigment changes, intensive subfoveal hard exudates)
- Apparent cataract, aphakia, pseudoexfoliation syndrome, intraocular hemorrhage resulting in decreased vision, rhegmatogenous retinal detachment, macular hole, diabetic retinopathy and diabetic macular disease which need to be treated, choroidal neovascularization (CNV) for any reason except for AMD (such as ocular histoplasmosis, pathologic myopia)
- Afferent pupillary defect(APD)
- Refractive media opacity and miosis which effect fundus examination
- Any eye of patient with active inflammation, such as conjunctivitis, keratitis, scleritis, uveitis and endophthalmitis
- Choroidal neovascularization (CNV) for other reason, such as diabetic retinopathy, fundus angioid streaks, ocular histoplasmosis, pathologic myopia, trauma
The treatment of the eye
- The studied eye received topical or grid photocoagulation more than twice or within 3 months before screening
- The studied eye received any intraocular surgery or laser treatment (such as macular translocation surgery, glaucoma filtering surgery, verteporfin photodynamic therapy, transpupillary thermotherapy, foveal photocoagulation surgery, cataract surgery, vitreous cutting surgery, optic nerve incision operation, YAG posterior capsular incision surgery, sheath incision surgery or filtering surgery) within 3 months before screening
- Any eye received antiangiogenic drugs (including any anti-VEGF drugs) (such as pegaptanib [Macugen®], Aflibercept [Eylea®], ranibizumab [Lucentis ®], bevacizumab [Avastin ®]) within 3 months before baseline visit
- Any eye received intraocular injection of corticosteroid drugs (such as triamcinolone acetonide), or periocular injection of corticosteroid drugs within 1 months before screening
Systemic diseases,treatment and other conditions
- With a history of allergy to sodium fluorescein and indocyanine green
- PLT≤100×109/L, BUN, Cr, thrombin time and prothrombin time beyond the upper limit of the normal range; take anti-platelet aggregation drugs within a month prior to enrollment
- With surgery within one month prior to enrollment, or with unhealing wound, ulcer, fracture at present
- Diabetic patients without the control of glucose or accompanied by diabetic retinopathy
- With a history of myocardial infarction within 6 months before enrolled
- With activity disseminated intravascular coagulation and a tendency of significant bleeding prior to enrollment
- Systemic autoimmune disease
- Any uncontrolled clinical problems (such as severe systemic diseases of mental, neurological, cardiovascular, respiratory and malignancies)
- Pregnant and lactating women and patients who cannot take contraceptive measures
- Poor compliance
- The patients who is considered unsuitable for enrollment by investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TK001 0.1mg
Injection:single Intravitreal Injection
|
Intravitreal Injection
|
Experimental: TK001 0.5mg
Injection:single Intravitreal Injection
|
Intravitreal Injection
|
Experimental: TK001 1.0mg
Injection:single Intravitreal Injection
|
Intravitreal Injection
|
Experimental: TK001 2.0mg
Biological: TK001 Injection:single Intravitreal Injection
|
Intravitreal Injection
|
Experimental: TK001 2.5mg
Biological: TK001 Injection:single Intravitreal Injection
|
Intravitreal Injection
|
Experimental: TK001 3.0mg
Injection:single Intravitreal Injection
|
Intravitreal Injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency of ocular and systemic AEs (adverse events) and SAEs (serious adverse events) which are related to TK001
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best Corrected Visual Acuity (BCVA)
Time Frame: 6 weeks
|
6 weeks
|
|
Area under the plasma concentration-time curve from time zero to infinity (AUCinf)
Time Frame: Up to Day 42
|
Up to Day 42
|
|
Area under the plasma concentration-time curve from time zero to time 't' where t is a defined time point after administration (AUC0-t)
Time Frame: Up to Day 42
|
Up to Day 42
|
|
Maximum observed maximum plasma concentration (Cmax)
Time Frame: Up to Day 42
|
Up to Day 42
|
|
Time to reach the maximum observed plasma concentration (Tmax)
Time Frame: Up to Day 42
|
Up to Day 42
|
|
Frequency of subjects with anti-TK001 antibody
Time Frame: Up to Day 42
|
Anti- TK001 antibody will be detected pre-dose,14d and 42d.
|
Up to Day 42
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2015
Primary Completion (Anticipated)
June 1, 2018
Study Completion (Anticipated)
September 1, 2018
Study Registration Dates
First Submitted
November 21, 2015
First Submitted That Met QC Criteria
November 21, 2015
First Posted (Estimate)
November 24, 2015
Study Record Updates
Last Update Posted (Actual)
March 1, 2018
Last Update Submitted That Met QC Criteria
February 27, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Tmab-TK001-AMD-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neovascular Age-related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
-
Hoffmann-La RocheCompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
Clinical Trials on TK001
-
Jiangsu T-Mab Biopharma Co.,LtdUnknownNeovascular Age-Related Macular DegenerationChina